KR100508289B1
(ko)
*
|
1998-04-21 |
2005-08-17 |
마이크로메트 에이지 |
Cd19×cd3 특이 폴리펩티드 및 그의 용도
|
DE60024436T2
(de)
|
1999-05-07 |
2006-08-17 |
Genentech, Inc., South San Francisco |
Behandlung von autoimmunkrankheiten mit antagonisten die oberflächenmarker von b zellen binden
|
US7074403B1
(en)
*
|
1999-06-09 |
2006-07-11 |
Immunomedics, Inc. |
Immunotherapy of autoimmune disorders using antibodies which target B-cells
|
US8383081B2
(en)
|
1999-05-10 |
2013-02-26 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods of use
|
US7829064B2
(en)
|
1999-05-10 |
2010-11-09 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods
|
US8119101B2
(en)
|
1999-05-10 |
2012-02-21 |
The Ohio State University |
Anti-CD74 immunoconjugates and methods of use
|
EP1543839B1
(en)
*
|
1999-06-09 |
2017-09-20 |
Immunomedics, Inc. |
Immunotherapy of autoimmune disorders using antibodies which target B-cells
|
DE19962583A1
(de)
*
|
1999-12-23 |
2001-06-28 |
Mueller Hermelink Hans Konrad |
Antikörper gegen Plasmazellen
|
ATE338124T1
(de)
|
2000-11-07 |
2006-09-15 |
Hope City |
Cd19-spezifische umgezielte immunzellen
|
US20160279239A1
(en)
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
US20080260731A1
(en)
*
|
2002-03-01 |
2008-10-23 |
Bernett Matthew J |
Optimized antibodies that target cd19
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US9453251B2
(en)
|
2002-10-08 |
2016-09-27 |
Pfenex Inc. |
Expression of mammalian proteins in Pseudomonas fluorescens
|
US7820166B2
(en)
|
2002-10-11 |
2010-10-26 |
Micromet Ag |
Potent T cell modulating molecules
|
JP2008501621A
(ja)
*
|
2003-05-31 |
2008-01-24 |
マイクロメット アクツィエン ゲゼルシャフト |
B細胞関連疾患を処置するための二重特異性抗cd3、抗cd19抗体構築物を含む薬学的組成物
|
SI1629011T1
(sl)
|
2003-05-31 |
2010-05-31 |
Micromet Ag |
Humane molekule za vezavo anti hu cd
|
JP2007522096A
(ja)
|
2003-06-06 |
2007-08-09 |
メディミューン,インコーポレーテッド |
癌の診断、治療、及び予防のためのEphA4及びEphA4変調因子の使用
|
WO2005012493A2
(en)
*
|
2003-07-31 |
2005-02-10 |
Immunomedics, Inc. |
Anti-cd19 antibodies
|
US7902338B2
(en)
|
2003-07-31 |
2011-03-08 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
DK1673398T3
(da)
*
|
2003-10-16 |
2011-04-18 |
Micromet Ag |
Multispecifikke, deimmuniserede CD3-bindere
|
ES2341252T3
(es)
*
|
2003-11-28 |
2010-06-17 |
Micromet Ag |
Composiciones que comprenden polipeptidos.
|
US7235641B2
(en)
*
|
2003-12-22 |
2007-06-26 |
Micromet Ag |
Bispecific antibodies
|
US9550838B2
(en)
|
2004-02-13 |
2017-01-24 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
US8883160B2
(en)
|
2004-02-13 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
SI1716178T1
(sl)
*
|
2004-02-16 |
2010-11-30 |
Micromet Ag |
Manj imunogene vezne molekule
|
EP1774017B1
(en)
|
2004-07-26 |
2013-05-15 |
Pfenex Inc. |
Process for improved protein expression by strain engineering
|
CA2585717A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
SG161292A1
(en)
|
2005-04-18 |
2010-05-27 |
Micromet Ag |
Antibody neutralizers of human granulocyte macrophage colony stimulating factor
|
CA2606081C
(en)
|
2005-04-26 |
2013-09-17 |
Markus M. Heiss |
Combination of the application of antibodies for immunostimulation together with glucocorticoids
|
WO2007002223A2
(en)
|
2005-06-20 |
2007-01-04 |
Medarex, Inc. |
Cd19 antibodies and their uses
|
EP2500352A1
(en)
*
|
2005-08-19 |
2012-09-19 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
AU2006301492B2
(en)
|
2005-10-11 |
2011-06-09 |
Amgen Research (Munich) Gmbh |
Compositions comprising cross-species-specific antibodies and uses thereof
|
SI1976886T1
(sl)
*
|
2005-12-16 |
2015-03-31 |
Amgen Research (Munich) Gmbh |
Sredstva in postopki za zdravljenje tumorskih bolezni
|
SG193141A1
(en)
|
2005-12-21 |
2013-09-30 |
Amgen Res Munich Gmbh |
Pharmaceutical compositions with resistance to soluble cea
|
PL1989544T3
(pl)
*
|
2006-03-02 |
2012-01-31 |
Antitope Ltd |
Testy na komórkach T
|
AU2007285976B2
(en)
|
2006-08-14 |
2011-08-18 |
Xencor, Inc |
Optimized antibodies that target CD19
|
MX2009002414A
(es)
*
|
2006-09-08 |
2009-05-20 |
Medimmune Llc |
Anticuerpos anti-cd19 humanizados y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunitaria.
|
WO2008119567A2
(en)
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Cross-species-specific cd3-epsilon binding domain
|
KR101626988B1
(ko)
*
|
2007-04-03 |
2016-06-02 |
암젠 리서치 (뮌헨) 게엠베하 |
종간 특이적 이중특이적인 결합제들
|
HUE040467T2
(hu)
|
2007-04-03 |
2019-03-28 |
Amgen Res Munich Gmbh |
Keresztfaj-specifikus kötõdomén
|
WO2008134461A2
(en)
|
2007-04-27 |
2008-11-06 |
Dow Global Technologies, Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
US9580719B2
(en)
|
2007-04-27 |
2017-02-28 |
Pfenex, Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
PL3327026T3
(pl)
|
2007-07-09 |
2020-02-28 |
Genentech, Inc. |
Zapobieganie redukcji wiązań disiarczkowych podczas rekombinacyjnego wytwarzania polipeptydów
|
KR101617243B1
(ko)
*
|
2007-07-31 |
2016-05-02 |
라이프스캔, 인코포레이티드 |
인간 배아 줄기 세포의 분화
|
WO2009018386A1
(en)
|
2007-07-31 |
2009-02-05 |
Medimmune, Llc |
Multispecific epitope binding proteins and uses thereof
|
US7968687B2
(en)
*
|
2007-10-19 |
2011-06-28 |
Seattle Genetics, Inc. |
CD19 binding agents and uses thereof
|
US9308257B2
(en)
|
2007-11-28 |
2016-04-12 |
Medimmune, Llc |
Protein formulation
|
KR101820535B1
(ko)
|
2008-10-01 |
2018-01-19 |
암젠 리서치 (뮌헨) 게엠베하 |
종간특이적 psmaxcd3 이중특이적 단일쇄 항체
|
JP6130097B2
(ja)
*
|
2008-10-01 |
2017-05-17 |
アムゲン リサーチ (ミュンヘン) ゲーエムベーハー |
PSCA×CD3、CD19×CD3、C−MET×CD3、エンドシアリン×CD3、EpCAM×CD3、IGF−1R×CD3、またはFAPアルファ×CD3の異種間特異的二重特異性単鎖抗体
|
US10981998B2
(en)
|
2008-10-01 |
2021-04-20 |
Amgen Research (Munich) Gmbh |
Cross-species-specific single domain bispecific single chain antibody
|
EP2352763B2
(en)
|
2008-10-01 |
2022-09-21 |
Amgen Research (Munich) GmbH |
Bispecific single chain antibodies with specificity for high molecular weight target antigens
|
EP3594237A1
(en)
*
|
2008-11-07 |
2020-01-15 |
Amgen Research (Munich) GmbH |
Treatment of pediatric acute lymphoblastic leukemia
|
BRPI0921482B1
(pt)
*
|
2008-11-07 |
2022-09-20 |
Amgen Research (Munich) Gmbh |
Uso de uma construção de anticorpo de cadeia simples biespecífica cd19xcd3 no tratamento de leucemia linfoblástica aguda
|
WO2010084160A1
(en)
|
2009-01-21 |
2010-07-29 |
Oryzon Genomics S.A. |
Phenylcyclopropylamine derivatives and their medical use
|
US9676845B2
(en)
*
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
NZ597259A
(en)
|
2009-06-23 |
2014-04-30 |
Alexion Pharma Inc |
Bispecific antibodies that bind to complement proteins
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
RU2602814C2
(ru)
|
2009-09-25 |
2016-11-20 |
Оризон Дженомикс С.А. |
Лизинспецифические ингибиторы деметилазы-1 и их применение
|
US8946296B2
(en)
|
2009-10-09 |
2015-02-03 |
Oryzon Genomics S.A. |
Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
|
JP6092625B2
(ja)
*
|
2009-10-27 |
2017-03-08 |
アムゲン リサーチ (ミュンヘン) ゲーエムベーハー |
CD19xCD3二重特異性抗体を投与するための投与計画
|
MX2012006406A
(es)
|
2009-12-04 |
2012-07-25 |
Genentech Inc |
Anticuerpos multiespecificos, analogos de anticuerpo, composiciones y metodos.
|
US20110165161A1
(en)
*
|
2009-12-23 |
2011-07-07 |
Shih-Yao Lin |
Anti-epcam antibodies that induce apoptosis of cancer cells and methods using same
|
US9616058B2
(en)
|
2010-02-24 |
2017-04-11 |
Oryzon Genomics, S.A. |
Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
|
WO2011106573A2
(en)
|
2010-02-24 |
2011-09-01 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
|
TWI653333B
(zh)
|
2010-04-01 |
2019-03-11 |
安進研究(慕尼黑)有限責任公司 |
跨物種專一性之PSMAxCD3雙專一性單鏈抗體
|
HUE030938T2
(en)
|
2010-04-19 |
2017-06-28 |
Oryzon Genomics Sa |
Lysine-specific demethylase-1 inhibitors and their use
|
KR20130079384A
(ko)
|
2010-05-03 |
2013-07-10 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 조성물 및 방법
|
JP5636091B2
(ja)
|
2010-05-05 |
2014-12-03 |
ウニベルジテート バイロイト |
癌治療に用いるためのコンブレタスタチン類似体
|
CN102250245B
(zh)
*
|
2010-05-27 |
2014-05-14 |
四川大学 |
抗b细胞淋巴瘤的双特异性抗体及其用途
|
WO2012013725A1
(en)
|
2010-07-28 |
2012-02-02 |
Medizinische Universität Wien |
Vinylogous chalcone derivatives and their medical use
|
WO2012013727A1
(en)
|
2010-07-29 |
2012-02-02 |
Oryzon Genomics S.A. |
Cyclopropylamine derivatives useful as lsd1 inhibitors
|
CN103124724B
(zh)
|
2010-07-29 |
2015-05-20 |
奥瑞泽恩基因组学股份有限公司 |
Lsd1的基于芳基环丙胺的脱甲基酶抑制剂及其医疗用途
|
WO2012016227A2
(en)
|
2010-07-29 |
2012-02-02 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
WO2012045883A1
(en)
|
2010-10-08 |
2012-04-12 |
Oryzon Genomics S.A. |
Cyclopropylamine inhibitors of oxidases
|
PT2632954E
(pt)
|
2010-10-27 |
2016-02-03 |
Amgen Res Munich Gmbh |
Meios e métodos para tratar dlbcl
|
EA026075B1
(ru)
|
2010-11-10 |
2017-02-28 |
Эмджен Рисерч (Мьюник) Гмбх |
Предотвращение неблагоприятных эффектов, вызванных cd3-специфическими связывающими доменами
|
US20130273055A1
(en)
*
|
2010-11-16 |
2013-10-17 |
Eric Borges |
Agents and methods for treating diseases that correlate with bcma expression
|
WO2012072713A2
(en)
|
2010-11-30 |
2012-06-07 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
|
EP2712315B1
(en)
|
2011-02-08 |
2021-11-24 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for myeloproliferative disorders
|
US20120213781A1
(en)
|
2011-02-11 |
2012-08-23 |
Zyngenia, Inc. |
Monovalent and Multivalent Multispecific Complexes and Uses Thereof
|
EP2701741B1
(en)
|
2011-04-28 |
2020-06-10 |
Amgen Research (Munich) GmbH |
Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects
|
SG10201509588TA
(en)
|
2011-05-21 |
2015-12-30 |
Macrogenics Inc |
CD3-Binding Molecules Capable Of Binding To Human And Non-Human CD3
|
CN106432506A
(zh)
|
2011-05-24 |
2017-02-22 |
泽恩格尼亚股份有限公司 |
多价和单价多特异性复合物及其用途
|
RU2014100111A
(ru)
|
2011-06-10 |
2015-07-20 |
МЕДИММЬЮН, ЭлЭлСи |
МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ
|
PT2744515T
(pt)
*
|
2011-08-16 |
2022-05-19 |
Morphosys Ag |
Terapia de combinação com um anticorpo anti-cd19 e uma mostarda de nitrogénio
|
DE102012016127A1
(de)
|
2011-08-31 |
2013-02-28 |
Daniel Elias |
Bioaktive, regenerative Mischung zur Herstellung eines Ergänzungsnahrungsmittels
|
WO2013041687A1
(en)
|
2011-09-23 |
2013-03-28 |
Amgen Research (Munich) Gmbh |
Bispecific binding molecules for 5t4 and cd3
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
RU2681211C2
(ru)
|
2011-10-20 |
2019-03-05 |
Оризон Дженомикс С.А. |
(гетеро)арилциклопропиламины в качестве ингибиторов lsd1
|
BR112014009238B1
(pt)
|
2011-10-20 |
2022-08-09 |
Oryzon Genomics S.A. |
Compostos de (hetero)aril ciclopropilamina, seus usos e composições farmacêuticas
|
LT2776065T
(lt)
|
2011-11-07 |
2020-10-12 |
Medimmune Limited |
Kombinuotos terapijos, panaudojančios prieš pseudomonas psl ir pcrv nukreiptas, juos surišančias molekules
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
US9757458B2
(en)
|
2011-12-05 |
2017-09-12 |
Immunomedics, Inc. |
Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
|
EP2788020A4
(en)
|
2011-12-05 |
2015-04-29 |
Immunomedics Inc |
THERAPEUTIC USE OF ANTI-CD22 ANTIBODIES FOR THE INDUCTION OF TROGO CYTOSIS
|
JP6363021B2
(ja)
*
|
2012-02-03 |
2018-07-25 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
抗原をトランスフェクトされたt細胞を伴う二重特異性抗体分子及び医薬におけるそれらの使用
|
JP2015513399A
(ja)
|
2012-02-22 |
2015-05-14 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
癌の治療のために有用なt細胞の存続的集団を作製するための組成物および方法
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
WO2013128027A1
(en)
|
2012-03-01 |
2013-09-06 |
Amgen Research (Munich) Gmbh |
Long life polypeptide binding molecules
|
CN103382223B
(zh)
|
2012-04-01 |
2015-06-10 |
上海益杰生物技术有限公司 |
针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
|
WO2014004549A2
(en)
|
2012-06-27 |
2014-01-03 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
CN104583230A
(zh)
|
2012-07-13 |
2015-04-29 |
宾夕法尼亚大学董事会 |
通过共同引入双特异性抗体增强car t细胞的活性
|
US9682143B2
(en)
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
CN109513003A
(zh)
|
2012-08-14 |
2019-03-26 |
Ibc药品公司 |
用于治疗疾病的t-细胞重定向双特异性抗体
|
US10131712B2
(en)
|
2012-08-14 |
2018-11-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
US20150231241A1
(en)
|
2012-08-14 |
2015-08-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
AR093297A1
(es)
|
2012-10-31 |
2015-05-27 |
Amgen Res (Munich) Gmbh |
Formulacion liquida que comprende un compuesto neutralizante de gm-csf
|
US9833410B2
(en)
|
2012-10-31 |
2017-12-05 |
Takeda Gmbh |
Lyophilized formulation comprising GM-CSF neutralizing compound
|
CN103833852A
(zh)
*
|
2012-11-23 |
2014-06-04 |
上海市肿瘤研究所 |
针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
JP6366111B2
(ja)
|
2012-12-13 |
2018-08-01 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
有効性の改善および毒性の減少のための、抗体およびsn−38からなるイムノコンジュゲートの投薬
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
US9107960B2
(en)
|
2012-12-13 |
2015-08-18 |
Immunimedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
EP3620473A1
(en)
|
2013-01-14 |
2020-03-11 |
Xencor, Inc. |
Novel heterodimeric proteins
|
AU2014207549B2
(en)
|
2013-01-15 |
2018-12-06 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
CN103965359B
(zh)
*
|
2013-01-24 |
2016-08-03 |
上海市肿瘤研究所 |
抗上皮细胞粘附分子和t细胞抗原的双特异性抗体
|
US9920121B2
(en)
|
2013-01-25 |
2018-03-20 |
Amgen Inc. |
Antibodies targeting CDH19 for melanoma
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
JO3529B1
(ar)
|
2013-02-08 |
2020-07-05 |
Amgen Res Munich Gmbh |
مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
|
US9486475B2
(en)
|
2013-02-08 |
2016-11-08 |
Amgen Research (Munich) Gmbh |
PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
|
WO2014138314A1
(en)
|
2013-03-05 |
2014-09-12 |
Baylor College Of Medicine |
Oncolytic virus
|
CA2904230A1
(en)
|
2013-03-05 |
2014-09-12 |
Baylor College Of Medicine |
Engager cells for immunotherapy
|
CA2906927C
(en)
|
2013-03-15 |
2021-07-13 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
CN105451767B
(zh)
|
2013-03-15 |
2019-10-18 |
泽恩格尼亚股份有限公司 |
多价和单价多特异性复合物及其用途
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res (Munich) Gmbh |
Moléculas de unión para bcma y cd3
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
US9561291B2
(en)
*
|
2013-03-15 |
2017-02-07 |
Imre Kovesdi |
Methods of targeting T-cells to tumors
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
US20140302037A1
(en)
*
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
WO2014144573A2
(en)
*
|
2013-03-15 |
2014-09-18 |
Memorial Sloan-Kettering Cancer Center |
Multimerization technologies
|
DK2970449T3
(da)
|
2013-03-15 |
2019-11-25 |
Amgen Res Munich Gmbh |
Enkeltkædede bindingsmolekyler, der omfatter n-terminal abp
|
US9505849B2
(en)
|
2013-03-15 |
2016-11-29 |
Amgen Research (Munich) Gmbh |
Antibody constructs for influenza M2 and CD3
|
CN104140974B
(zh)
*
|
2013-05-08 |
2017-09-29 |
科济生物医药(上海)有限公司 |
编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
|
US10077312B2
(en)
|
2013-05-10 |
2018-09-18 |
Numab Therapeutics AG |
CD3 and IL-23 receptor binding bispecific constructs and their use in the treatment of various diseases
|
WO2015006482A1
(en)
*
|
2013-07-09 |
2015-01-15 |
Duke University |
CERTAIN IMPROVED HUMAN BISPECIFIC EGFRvIII ANTIBODY ENGAGING MOLECULES
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
CN104342453A
(zh)
*
|
2013-08-06 |
2015-02-11 |
深圳先进技术研究院 |
含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
|
BR112016003293A8
(pt)
|
2013-08-30 |
2022-08-16 |
Takeda Gmbh |
Anticorpos neutralizantes de gm-csf para utilização no tratamento de artrite reumatoide ou como analgésicos
|
AR097648A1
(es)
|
2013-09-13 |
2016-04-06 |
Amgen Inc |
Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
|
WO2015054691A2
(en)
|
2013-10-11 |
2015-04-16 |
The United States Of America, As Pepresented By The Secretary, Department Of Health And Human Services |
Tem8 antibodies and their use
|
CN104623637A
(zh)
|
2013-11-07 |
2015-05-20 |
健能隆医药技术(上海)有限公司 |
Il-22二聚体在制备静脉注射药物中的应用
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
MX2016010683A
(es)
*
|
2014-02-21 |
2017-05-11 |
Ibc Pharmaceuticals Inc |
Terapia para tratar enfermedades mediante la induccion de respuesta inmune de las células que expresan trop-2.
|
WO2015130416A1
(en)
|
2014-02-25 |
2015-09-03 |
Immunomedics, Inc. |
Humanized rfb4 anti-cd22 antibody
|
TWI701042B
(zh)
|
2014-03-19 |
2020-08-11 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
ME03666B
(me)
|
2014-03-28 |
2020-10-20 |
Xencor Inc |
Bispecifična antitela koja se vezuju za cd38 i cd3
|
RU2577226C2
(ru)
*
|
2014-04-10 |
2016-03-10 |
Общество с ограниченной ответственностью, "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") |
Способ получения биспецифических антител против cd3*cd19 формата флексибоди в клетках млекопитающих
|
RU2568910C2
(ru)
*
|
2014-04-18 |
2015-11-20 |
Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") |
Фармацевтические композиции на основе флексибоди против cd3*cd19 для лечения в-клеточных заболеваний
|
CN105017422A
(zh)
*
|
2014-04-30 |
2015-11-04 |
山东百因制药技术有限公司 |
一种抗cd3/抗cd19双特异性抗体及其应用
|
MX2016014411A
(es)
|
2014-05-07 |
2017-04-06 |
Takeda Gmbh |
Formulacion liquida que comprende un compuesto neutralizante de gm-csf.
|
WO2015172341A1
(zh)
*
|
2014-05-14 |
2015-11-19 |
上海市肿瘤研究所 |
针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
|
EP2947460A1
(en)
|
2014-05-22 |
2015-11-25 |
Medizinische Universität Wien |
Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists
|
EP3531133B1
(en)
|
2014-05-30 |
2023-08-23 |
Amgen Research (Munich) GmbH |
Risk-stratification of b-precursor acute lymphoblastic leukemia patients
|
BR112016030740A2
(pt)
|
2014-07-01 |
2018-02-20 |
Pfizer Inc. |
diacorpos heterodiméricos biespecíficos e seus usos
|
WO2016014974A2
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
AU2015294834B2
(en)
|
2014-07-31 |
2021-04-29 |
Amgen Research (Munich) Gmbh |
Optimized cross-species specific bispecific single chain antibody constructs
|
TW201609811A
(zh)
|
2014-07-31 |
2016-03-16 |
安美基研究(慕尼黑)公司 |
具有增強之組織分布之雙特異性單鏈抗體構築體
|
AR101669A1
(es)
|
2014-07-31 |
2017-01-04 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
US10280156B2
(en)
|
2014-08-28 |
2019-05-07 |
Medizinische Universität Wien |
Heteroaromatic chalcone derivatives and their medical use
|
US10160795B2
(en)
|
2014-11-14 |
2018-12-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to Ebola virus glycoprotein and their use
|
PL3221359T3
(pl)
|
2014-11-17 |
2020-11-16 |
Regeneron Pharmaceuticals, Inc. |
Sposoby leczenia nowotworów przy użyciu dwuswoistego przeciwciała CD3XCD20
|
EP3223845B1
(en)
|
2014-11-26 |
2021-05-19 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd20
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
KR20170084327A
(ko)
|
2014-11-26 |
2017-07-19 |
젠코어 인코포레이티드 |
Cd3 및 cd38에 결합하는 이형이량체 항체
|
EP3029067A1
(en)
|
2014-12-01 |
2016-06-08 |
Deutsches Krebsforschungszentrum |
Use of blocking-reagents for reducing unspecific T cell-activation
|
WO2016094834A2
(en)
|
2014-12-12 |
2016-06-16 |
Alexion Pharmaceuticals, Inc. |
A method for treating a complement mediated disorder caused by an infectious agent in a patient
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
MA40801A1
(fr)
|
2015-01-23 |
2018-07-31 |
Sanofi Sa |
Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
|
WO2016135137A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
WO2016135139A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
BR112017017825A2
(pt)
|
2015-02-23 |
2018-04-10 |
Seagull Therapeutics Sas |
semaforinas 3 não naturais e seu uso médico
|
WO2016135138A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
|
WO2016135140A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
|
KR20210096326A
(ko)
|
2015-02-24 |
2021-08-04 |
바이오아트라, 인코퍼레이티드 |
조건부 활성 생체 단백질
|
EP3261665A1
(en)
|
2015-02-24 |
2018-01-03 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
EP3064507A1
(en)
|
2015-03-06 |
2016-09-07 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
|
WO2016154003A1
(en)
|
2015-03-20 |
2016-09-29 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Neutralizing antibodies to gp120 and their use
|
US20180084766A1
(en)
*
|
2015-04-07 |
2018-03-29 |
The Children's Medical Center Corporation |
Methods and compositions relating to an embryonic stem cell-based tumor model
|
LT3283524T
(lt)
|
2015-04-17 |
2023-05-25 |
Amgen Research (Munich) Gmbh |
Bispecifiniai antikūnų konstruktai, skirti cdh3 ir cd3
|
US9797907B2
(en)
|
2015-04-22 |
2017-10-24 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
|
WO2016170102A1
(en)
|
2015-04-22 |
2016-10-27 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Combination of an antiandrogen with a vitamin k antagonist or with a gamma -glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
|
PL3294768T3
(pl)
|
2015-05-13 |
2020-03-31 |
Ablynx N.V. |
Polipeptydy rekrutujące komórki T oparte na reaktywności TCR alfa/beta
|
CN114920847A
(zh)
|
2015-05-13 |
2022-08-19 |
埃博灵克斯股份有限公司 |
基于cd3反应性的t细胞募集多肽
|
JP2018516248A
(ja)
|
2015-05-29 |
2018-06-21 |
アンフィヴェナ セラピューティクス,インク. |
二重特異性のcd33およびcd3結合タンパク質を使用する方法
|
WO2016196975A1
(en)
|
2015-06-03 |
2016-12-08 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
CN106349391A
(zh)
*
|
2015-07-17 |
2017-01-25 |
中国科学院深圳先进技术研究院 |
Hbv特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环dna及应用
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
JO3620B1
(ar)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
US11713358B2
(en)
|
2015-08-28 |
2023-08-01 |
Amunix Pharmaceuticals, Inc. |
Chimeric polypeptide assembly and methods of making and using the same
|
JP2018528218A
(ja)
|
2015-09-11 |
2018-09-27 |
アンドリアン、ブルース |
組換えグリコシル化エクリズマブおよびエクリズマブ変異体
|
MA44909A
(fr)
|
2015-09-15 |
2018-07-25 |
Acerta Pharma Bv |
Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
JP6937746B2
(ja)
|
2015-10-02 |
2021-09-22 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性抗cd19×cd3t細胞活性化抗原結合分子
|
US11203634B2
(en)
|
2015-10-07 |
2021-12-21 |
Alexion Pharmaceuticals, Inc. |
Methods of treating age-related macular degeneration in a patient comprising administering an anti-C5a antibody
|
US10392441B2
(en)
|
2015-10-07 |
2019-08-27 |
United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
|
EP3371349A1
(en)
|
2015-11-02 |
2018-09-12 |
Bioatla, LLC |
Conditionally active polypeptides
|
CN108884149B
(zh)
|
2015-11-03 |
2022-07-01 |
美国政府(由卫生和人类服务部的部长所代表) |
Hiv-1 gp41中和抗体及其用途
|
CN105296421B
(zh)
*
|
2015-11-24 |
2019-01-29 |
高岱清 |
一种双特异性抗体活化的t细胞及制备方法与应用
|
RU2651776C2
(ru)
*
|
2015-12-01 |
2018-04-23 |
Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") |
Биспецифические антитела против cd3*cd19
|
JP7058219B2
(ja)
|
2015-12-07 |
2022-04-21 |
ゼンコア インコーポレイテッド |
Cd3及びpsmaに結合するヘテロ二量体抗体
|
HUE056897T2
(hu)
|
2015-12-09 |
2022-03-28 |
Univ Wien Med |
Monomaleimid-funkcionalizált platinavegyületek rákterápiához
|
WO2017106061A1
(en)
|
2015-12-14 |
2017-06-22 |
Macrogenics, Inc. |
Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
|
KR20180101623A
(ko)
|
2016-02-03 |
2018-09-12 |
암젠 리서치 (뮌헨) 게엠베하 |
Psma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물
|
EP3411402B1
(en)
|
2016-02-03 |
2021-12-22 |
Amgen Research (Munich) GmbH |
Bcma and cd3 bispecific t cell engaging antibody constructs
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
US20170224837A1
(en)
|
2016-02-10 |
2017-08-10 |
Immunomedics, Inc. |
Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
|
EP3416947A1
(en)
|
2016-02-15 |
2018-12-26 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Taf1 inhibitors for the therapy of cancer
|
EP3216458A1
(en)
|
2016-03-07 |
2017-09-13 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Modified vascular endothelial growth factor a (vegf-a) and its medical use
|
US20190112380A1
(en)
|
2016-03-29 |
2019-04-18 |
University Of Southern California |
Chimeric antigen receptors targeting cancer
|
WO2017167350A1
(en)
*
|
2016-03-30 |
2017-10-05 |
Horst Lindhofer |
Multispecific antibodies for use in the treatment of a neoplasm of the urinary tract
|
IL295538B2
(en)
*
|
2016-04-13 |
2024-02-01 |
Vivia Biotech Sl |
In vitro bite-activated T cells
|
EP3442562B1
(en)
|
2016-04-15 |
2022-09-21 |
Evive Biotechnology (Shanghai) Ltd |
An il-22 dimer for use in treating necrotizing enterocolitis
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
RU2725292C2
(ru)
|
2016-04-27 |
2020-06-30 |
Иммьюномедикс, Инк. |
Эффективность конъюгатов антитела против trop-2 с лекарственным средством sn-38 для терапии рецидивирующих/рефрактерных к ингибиторам контрольной точки опухолей
|
WO2017192589A1
(en)
|
2016-05-02 |
2017-11-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to influenza ha and their use and identification
|
CN105906720A
(zh)
*
|
2016-05-16 |
2016-08-31 |
武汉汉密顿生物科技股份有限公司 |
靶向性嵌合抗原受体修饰的免疫细胞及其制备方法和应用
|
RU2022104399A
(ru)
|
2016-06-14 |
2022-05-05 |
Ксенкор, Инк. |
Биспецифические антитела-ингибиторы контрольных точек
|
US10669338B2
(en)
|
2016-06-17 |
2020-06-02 |
Immunomedics, Inc. |
Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1
|
US10316088B2
(en)
|
2016-06-28 |
2019-06-11 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
BR112019000015A2
(pt)
|
2016-06-30 |
2019-04-24 |
Oncorus, Inc. |
distribuição por vírus oncolítico pseudotipado de polipeptídeos terapêuticos
|
TWI790206B
(zh)
|
2016-07-18 |
2023-01-21 |
法商賽諾菲公司 |
特異性結合至cd3和cd123的雙特異性抗體樣結合蛋白
|
US11584780B2
(en)
|
2016-07-26 |
2023-02-21 |
Biomarin Pharmaceutical Inc. |
Adeno-associated virus capsid proteins
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
WO2018049261A1
(en)
|
2016-09-09 |
2018-03-15 |
Icellhealth Consulting Llc |
Oncolytic virus expressing immune checkpoint modulators
|
US20190307799A1
(en)
|
2016-09-23 |
2019-10-10 |
The Regents Of The University Of Michigan |
Engineered lymphocytes
|
KR102562519B1
(ko)
|
2016-10-14 |
2023-08-02 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα FC-융합 단백질 및 PD-1 항체 단편을 포함하는 이중특이성 이종이량체 융합 단백질
|
EP3529618B1
(en)
|
2016-10-19 |
2020-12-02 |
Alexion Pharmaceuticals, Inc. |
A method of quantitating unbound c5 in a sample
|
WO2018087401A2
(en)
|
2016-11-14 |
2018-05-17 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Combination of a brd4 inhibitor and an antifolate for the therapy of cancer
|
BR112019010061A2
(pt)
|
2016-11-16 |
2019-08-13 |
Ablynx Nv |
polipeptídeos de recrutamento de células t capazes de se ligarem ao cd123 e tcr alfa/beta
|
EP3556772A4
(en)
*
|
2016-12-13 |
2020-09-09 |
Carsgen Therapeutics Ltd |
HUMANIZED ANTI-CD19 ANTIBODY AND TARGETING IMMUNE EFFICIENT CELL CD19
|
CN108264566B
(zh)
*
|
2016-12-30 |
2021-05-14 |
惠和生物技术(上海)有限公司 |
一种融合抗cd3抗体结构域和t细胞正共刺激分子配体的双特异性分子及其应用
|
CN108264557B
(zh)
*
|
2016-12-30 |
2021-08-24 |
惠和生物技术(上海)有限公司 |
一种结合cd3和t细胞负共刺激分子的双功能分子及其应用
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
AU2018219887A1
(en)
|
2017-02-08 |
2019-08-22 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
|
EP3580235B1
(en)
|
2017-02-10 |
2024-05-01 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
ES2955074T3
(es)
|
2017-02-20 |
2023-11-28 |
Dragonfly Therapeutics Inc |
Proteínas que se unen a HER2, NKG2D Y CD16
|
KR102585848B1
(ko)
|
2017-02-24 |
2023-10-11 |
마크로제닉스, 인크. |
Cd137 및 종양 항원에 결합할 수 있는 이중특이적 결합 분자, 및 그것의 용도
|
JP2020512314A
(ja)
|
2017-03-27 |
2020-04-23 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
サシツズマブゴビテカンとRAD51阻害剤を用いたTrop−2発現トリプルネガティブ乳癌の治療
|
CN108659112B
(zh)
*
|
2017-03-30 |
2021-01-26 |
上海市同济医院 |
一种非对称双特异性抗体
|
CA3044082A1
(en)
|
2017-04-03 |
2018-10-11 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
US11236151B2
(en)
|
2017-04-25 |
2022-02-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection
|
KR102663596B1
(ko)
|
2017-04-26 |
2024-05-10 |
유레카 쎄라퓨틱스, 인코포레이티드 |
글리피칸 3을 특이적으로 인식하는 구축물 및 그의 용도
|
KR20190141243A
(ko)
|
2017-05-05 |
2019-12-23 |
암젠 인크 |
개선된 저장 및 투여를 위한 이중특이적 항체 구축물을 포함하는 약제학적 조성물
|
WO2018224441A1
(en)
|
2017-06-05 |
2018-12-13 |
Numab Innovation Ag |
Novel anti-cd3 antibodies
|
US20200157224A1
(en)
|
2017-06-25 |
2020-05-21 |
Systimmune, Inc. |
Multi-specific antibodies and methods of making and using thereof
|
MA49517A
(fr)
|
2017-06-30 |
2020-05-06 |
Xencor Inc |
Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène
|
CN111094334A
(zh)
|
2017-07-19 |
2020-05-01 |
美国卫生与公众服务部 |
用于诊断和***病毒感染的抗体和方法
|
BR122021015266B1
(pt)
|
2017-08-03 |
2023-01-24 |
Amgen Inc. |
Conjugado compreendendo muteína de il-21 e anticorpo anti-pd, kit e composição farmacêutica
|
ES2928576T3
(es)
|
2017-09-08 |
2022-11-21 |
Amgen Inc |
Inhibidores de KRAS G12C y métodos de uso de los mismos
|
IL273119B2
(en)
|
2017-09-08 |
2023-10-01 |
Maverick Therapeutics Inc |
Binding proteins are activated under limited conditions
|
SG11202001449VA
(en)
|
2017-09-15 |
2020-03-30 |
Amgen Inc |
Process for lyophilized pharmaceutical formulation of a therapeutic protein
|
JP2020536967A
(ja)
|
2017-10-12 |
2020-12-17 |
イミュノウェイク インコーポレイテッド |
Vegfr−抗体軽鎖融合タンパク質
|
US20200262919A1
(en)
|
2017-10-13 |
2020-08-20 |
Merck Sharp & Dohme Corp. |
Compositions and methods for treating diffuse large b cell lymphoma
|
KR20200064096A
(ko)
|
2017-10-14 |
2020-06-05 |
싸이톰스 테라퓨틱스, 인크. |
항체, 활성화 가능한 항체, 이중특이적 항체 및 이중특이적 활성화 가능한 항체 및 이들의 사용 방법
|
CN107739410B
(zh)
*
|
2017-10-18 |
2021-07-30 |
南京鼓楼医院 |
CD3单链抗体-iRGD融合蛋白、制备及其作为抗肿瘤药物的应用
|
WO2019086331A2
(en)
|
2017-11-02 |
2019-05-09 |
Bayer Aktiengesellschaft |
Bispecific antibodies binding alk-1 and bmpr-2
|
KR20200085828A
(ko)
|
2017-11-08 |
2020-07-15 |
젠코어 인코포레이티드 |
신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
TWI827570B
(zh)
|
2017-12-11 |
2024-01-01 |
美商安進公司 |
雙特異性抗體產品之連續製造製程
|
SG11202005557TA
(en)
|
2017-12-12 |
2020-07-29 |
Macrogenics Inc |
Bispecific cd 16-binding molecules and their use in the treatment of disease
|
MX2020006322A
(es)
|
2017-12-19 |
2020-09-18 |
Xencor Inc |
Proteinas de fusion il-2 fc modificadas.
|
US11865081B2
(en)
|
2017-12-29 |
2024-01-09 |
Virogin Biotech Canada Ltd. |
Oncolytic viral delivery of therapeutic polypeptides
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對muc17和cd3之雙特異性抗體構建體
|
US11976109B2
(en)
|
2018-01-02 |
2024-05-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to ebola virus glycoprotein and their use
|
CN107987169B
(zh)
*
|
2018-01-05 |
2021-10-08 |
阿思科力(苏州)生物科技有限公司 |
一种以ROBO1为靶点的双特异性抗体scFv及其制备和应用
|
JP2019122373A
(ja)
|
2018-01-12 |
2019-07-25 |
アムジエン・インコーポレーテツド |
抗pd−1抗体及び治療方法
|
BR112020016190A2
(pt)
|
2018-02-08 |
2020-12-15 |
Dragonfly Therapeutics, Inc. |
Domínios variáveis de anticorpos direcionando o receptor nkg2d
|
US11685781B2
(en)
|
2018-02-15 |
2023-06-27 |
Macrogenics, Inc. |
Variant CD3-binding domains and their use in combination therapies for the treatment of disease
|
AU2019226034A1
(en)
|
2018-02-21 |
2020-10-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to HIV-1 Env and their use
|
WO2019166650A1
(en)
|
2018-03-02 |
2019-09-06 |
Cdr-Life Ag |
Trispecific antigen binding proteins
|
WO2019177011A1
(ja)
*
|
2018-03-13 |
2019-09-19 |
国立大学法人大阪大学 |
腫瘍免疫賦活剤
|
US20190284288A1
(en)
|
2018-03-19 |
2019-09-19 |
The Regents Of The University Of Michigan |
Compositions and methods for t-cell and cytokine activation
|
AU2019247415A1
(en)
|
2018-04-04 |
2020-10-22 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
CN112437777A
(zh)
|
2018-04-18 |
2021-03-02 |
Xencor股份有限公司 |
包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白
|
WO2019204665A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
WO2019207051A1
(en)
|
2018-04-25 |
2019-10-31 |
Università Degli Studi Di Torino |
Medical use of combinations of non-natural semaphorins 3 and antimetabolites
|
US20210171610A1
(en)
|
2018-05-02 |
2021-06-10 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
BR112020022722A8
(pt)
|
2018-05-09 |
2022-01-18 |
Biomarin Pharm Inc |
Genoma e seu uso, vetor, partícula, molécula de ácido nucleico isolada, ácido nucleico, composição, tratamento, método
|
TW202005978A
(zh)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
新穎肝靶向腺相關病毒載體
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
JOP20200343A1
(ar)
|
2018-07-02 |
2020-12-31 |
Xencor Inc |
بروتين ربط مولد ضد مضاد لـ steap1
|
EP3830121A1
(en)
|
2018-07-30 |
2021-06-09 |
Amgen Research (Munich) GmbH |
Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
|
WO2020025596A1
(en)
|
2018-07-31 |
2020-02-06 |
Amgen Research (Munich) Gmbh |
Dosing regimen for bcma-cd3 bispecific antibodies
|
BR112021002032A2
(pt)
|
2018-08-03 |
2021-07-20 |
Amgen Research (Munich) Gmbh |
construtos de anticorpos para cldn18.2 e cd3
|
AU2019331024A1
(en)
|
2018-08-31 |
2021-03-18 |
Regeneron Pharmaceuticals, Inc. |
Dosing strategy that mitigates cytokine release syndrome for CD3/C20 bispecific antibodies
|
US11066476B2
(en)
|
2018-09-14 |
2021-07-20 |
Shanghai tongji hospital |
Asymmetric bispecific antibody
|
CN110590955B
(zh)
*
|
2018-09-17 |
2021-05-18 |
北京盛诺基医药科技股份有限公司 |
一种双特异性抗体
|
MA53724A
(fr)
|
2018-09-24 |
2021-12-29 |
Amgen Inc |
Systèmes et procédés de dosage interventionnel
|
UY38393A
(es)
|
2018-09-28 |
2020-03-31 |
Amgen Inc |
Anticuerpos contra bcma soluble
|
CA3115096A1
(en)
|
2018-10-03 |
2020-04-09 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
JP2022512636A
(ja)
|
2018-10-11 |
2022-02-07 |
アムジエン・インコーポレーテツド |
二重特異性抗体コンストラクトの下流プロセシング
|
US20220128474A1
(en)
|
2018-10-23 |
2022-04-28 |
Amgen Inc. |
Automatic calibration and automatic maintenance of raman spectroscopic models for real-time predictions
|
JP2022507718A
(ja)
|
2018-11-20 |
2022-01-18 |
コーネル ユニバーシティー |
放射線核種の大環状錯体およびがんの放射線療法におけるそれらの使用
|
EP3883609A2
(en)
|
2018-12-20 |
2021-09-29 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
|
TW202043253A
(zh)
|
2019-01-28 |
2020-12-01 |
美商安進公司 |
藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
|
JP2022521200A
(ja)
|
2019-02-20 |
2022-04-06 |
アムジエン・インコーポレーテツド |
タンパク質の安定性を決定する方法
|
US11472890B2
(en)
|
2019-03-01 |
2022-10-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind ENPP3 and CD3
|
CN114390938A
(zh)
|
2019-03-05 |
2022-04-22 |
武田药品工业有限公司 |
受约束的条件性活化的结合蛋白
|
WO2020198538A1
(en)
|
2019-03-27 |
2020-10-01 |
Amgen Inc. |
Methods of fingerprinting therapeutic proteins via a two-dimensional (2d) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products
|
WO2020221792A1
(en)
|
2019-04-30 |
2020-11-05 |
Amgen Research (Munich) Gmbh |
Means and methods of treating burkitt lymphoma or leukemia
|
EP3962523A2
(en)
|
2019-05-03 |
2022-03-09 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
US20230085439A1
(en)
|
2019-05-21 |
2023-03-16 |
University Of Georgia Research Foundation, Inc. |
Antibodies that bind human metapneumovirus fusion protein and their use
|
WO2020247854A1
(en)
|
2019-06-07 |
2020-12-10 |
Amgen Inc. |
Bispecific binding constructs with selectively cleavable linkers
|
EP3983520A1
(en)
|
2019-06-13 |
2022-04-20 |
Amgen, Inc |
Automated biomass-based perfusion control in the manufacturing of biologics
|
CA3142833A1
(en)
|
2019-07-02 |
2021-01-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind egfrviii and their use
|
CN110623921B
(zh)
*
|
2019-08-15 |
2020-10-30 |
北京东方百泰生物科技股份有限公司 |
一种抗cd3和抗cd19的双特异性抗体注射制剂
|
RU2738802C1
(ru)
*
|
2019-08-21 |
2020-12-17 |
Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" |
Определяющие комплементарность участки для связывания cd3 и содержащая их биспецифическая антигенсвязывающая молекула
|
GB201912681D0
(en)
|
2019-09-04 |
2019-10-16 |
Eth Zuerich |
Bispecific binding agent that binds to cd117/c-kit and cd3
|
JP2022547135A
(ja)
|
2019-09-10 |
2022-11-10 |
アムジエン・インコーポレーテツド |
増強されたプロテインl捕捉動的結合容量を有する二重特異性抗原結合ポリペプチドの精製方法
|
AU2020360970A1
(en)
|
2019-10-02 |
2022-05-26 |
Domain Therapeutics |
Prostaglandin E2 (PGE2) EP4 receptor antagonists
|
IL292153A
(en)
|
2019-10-16 |
2022-06-01 |
Cemm Forschungszentrum Fur Molekulare Medizin Gmbh |
Oxazole and thiazole choline ubiquitin ligase ring compounds and uses thereof
|
WO2021074418A1
(en)
|
2019-10-16 |
2021-04-22 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof
|
EP3808741A1
(en)
|
2019-10-16 |
2021-04-21 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Compounds for targeted degradation of carrier proteins and uses thereof
|
WO2021091906A1
(en)
|
2019-11-04 |
2021-05-14 |
Amgen Inc. |
Methods for treating leukemia
|
EP3819312A1
(en)
|
2019-11-10 |
2021-05-12 |
Amgen, Inc |
Dosing regimen for anti-dll3 agents
|
EP3819007A1
(en)
|
2019-11-11 |
2021-05-12 |
Amgen Research (Munich) GmbH |
Dosing regimen for anti-bcma agents
|
WO2021097344A1
(en)
|
2019-11-13 |
2021-05-20 |
Amgen Inc. |
Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
|
EP4093771A1
(en)
|
2020-01-22 |
2022-11-30 |
Amgen Research (Munich) GmbH |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
WO2021154839A1
(en)
|
2020-01-30 |
2021-08-05 |
Umoja Biopharma, Inc. |
Bispecific transduction enhancer
|
WO2021158469A1
(en)
|
2020-02-03 |
2021-08-12 |
Amgen Inc. |
Multivariate bracketing approach for sterile filter validation
|
TW202140561A
(zh)
|
2020-02-14 |
2021-11-01 |
日商協和麒麟股份有限公司 |
與cd3結合之雙特異性抗體
|
CN115151573A
(zh)
|
2020-02-28 |
2022-10-04 |
上海复宏汉霖生物技术股份有限公司 |
抗cd137构建体、多特异性抗体及其用途
|
BR112022016491A2
(pt)
|
2020-02-28 |
2022-10-11 |
Shanghai Henlius Biotech Inc |
Construto anti-cd137 e usos do mesmo
|
WO2021183207A1
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY OF NPM1c-POSITIVE CANCER
|
TW202200615A
(zh)
|
2020-03-12 |
2022-01-01 |
美商安進公司 |
用於治療和預防患者的crs之方法
|
IL296601A
(en)
|
2020-03-19 |
2022-11-01 |
Amgen Inc |
Antibodies against mucin 17 and their uses
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
US20220017636A1
(en)
|
2020-05-19 |
2022-01-20 |
Amgen Inc. |
Mageb2 binding constructs
|
TW202210101A
(zh)
|
2020-05-29 |
2022-03-16 |
美商安進公司 |
與cd33和cd3結合的雙特異性構建體的減輕不良反應投與
|
CN116529260A
(zh)
|
2020-06-02 |
2023-08-01 |
当康生物技术有限责任公司 |
抗cd93构建体及其用途
|
TW202210515A
(zh)
|
2020-06-02 |
2022-03-16 |
美商當康生物科技有限公司 |
抗cd39之構築體及其用途
|
CA3184351A1
(en)
|
2020-06-04 |
2021-12-09 |
Amgen Inc. |
Bispecific binding constructs
|
KR20230133832A
(ko)
|
2020-07-29 |
2023-09-19 |
다이내믹큐어 바이오테크놀로지 엘엘씨 |
항-cd93 구축물 및 그의 용도
|
EP4200332A1
(en)
|
2020-08-19 |
2023-06-28 |
Xencor, Inc. |
Anti-cd28 and/or anti-b7h3 compositions
|
KR20230057351A
(ko)
|
2020-08-27 |
2023-04-28 |
각코우호우진 쥰텐도 |
항절단형 변이 calr-cd3 이중특이성 항체 및 의약 조성물
|
AU2021340708A1
(en)
|
2020-09-11 |
2023-04-13 |
Amgen Inc. |
Materials and methods to reduce protein aggregation
|
EP4214233A1
(en)
|
2020-09-16 |
2023-07-26 |
Amgen Inc. |
Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
|
WO2022060878A1
(en)
|
2020-09-16 |
2022-03-24 |
Amgen Inc. |
Methods for treating prostate cancer
|
EP4229037A2
(en)
|
2020-10-16 |
2023-08-23 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
|
BR112023008629A2
(pt)
|
2020-11-06 |
2023-10-03 |
Amgen Inc |
Construtos de polipeptídeos que se ligam seletivamente a cldn6 e cd3
|
CN116635421A
(zh)
|
2020-11-06 |
2023-08-22 |
安进公司 |
与cd3结合的多肽构建体
|
EP4240768A2
(en)
|
2020-11-06 |
2023-09-13 |
Amgen Inc. |
Multitargeting bispecific antigen-binding molecules of increased selectivity
|
US20230406887A1
(en)
|
2020-11-06 |
2023-12-21 |
Amegen Inc. |
Antigen binding domain with reduced clipping rate
|
WO2022103781A1
(en)
|
2020-11-10 |
2022-05-19 |
Amgen Inc. |
Methods for administering a bcma x cd3 binding molecule
|
EP4255931A1
(en)
|
2020-12-03 |
2023-10-11 |
Amgen Inc. |
Immunoglobuline constructs with multiple binding domains
|
WO2022132904A1
(en)
|
2020-12-17 |
2022-06-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies targeting sars-cov-2
|
US20240092919A1
(en)
|
2020-12-18 |
2024-03-21 |
Ablynx N. V. |
T cell recruiting polypeptides based on tcr alpha/beta reactivity
|
CN116917326A
(zh)
|
2021-01-22 |
2023-10-20 |
博泰康医药公司 |
抗her-2/trop-2构建体及其用途
|
CN116963774A
(zh)
|
2021-01-28 |
2023-10-27 |
瑞泽恩制药公司 |
用于治疗细胞因子释放综合征的组合物和方法
|
US20240117019A1
(en)
|
2021-02-09 |
2024-04-11 |
University Of Georgia Research Foundation, Inc. |
Human monoclonal antibodies against pneumococcal antigens
|
KR20230142790A
(ko)
|
2021-02-09 |
2023-10-11 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
코로나바이러스 스파이크 단백질(spike protein)을 타겟팅하는 항체
|
CN114452403A
(zh)
|
2021-02-10 |
2022-05-10 |
同润生物医药(上海)有限公司 |
一种含有双功能免疫检查点/TGFβ抑制剂的药物组合
|
CA3212665A1
(en)
|
2021-03-09 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
KR20230154908A
(ko)
|
2021-03-10 |
2023-11-09 |
암젠 인크 |
재조합 단백질의 정제 방법
|
JP2024509878A
(ja)
|
2021-03-10 |
2024-03-05 |
アムジエン・インコーポレーテツド |
パラレルクロマトグラフィーシステム及び方法
|
WO2022192586A1
(en)
|
2021-03-10 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
US20240150466A1
(en)
|
2021-03-25 |
2024-05-09 |
Dynamicure Biotechnology Llc |
Anti-igfbp7 constructs and uses thereof
|
CN112794916B
(zh)
*
|
2021-04-08 |
2021-08-10 |
正大天晴药业集团南京顺欣制药有限公司 |
三特异性抗原结合构建体及构建方法和应用
|
WO2022234102A1
(en)
|
2021-05-06 |
2022-11-10 |
Amgen Research (Munich) Gmbh |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
WO2022266660A1
(en)
|
2021-06-17 |
2022-12-22 |
Amberstone Biosciences, Inc. |
Anti-cd3 constructs and uses thereof
|
KR20240058167A
(ko)
|
2021-09-17 |
2024-05-03 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
Sars-cov-2 중화 항체 동정을 위한 합성 인간화 라마 나노바디 라이브러리 및 이의 용도
|
AU2022364154A1
(en)
|
2021-10-15 |
2024-04-04 |
Amgen Research (Munich) Gmbh |
Subcutaneous administration of cd19-binding t cell engaging antibodies
|
WO2023076318A1
(en)
|
2021-10-27 |
2023-05-04 |
Amgen Inc. |
Deep learning-based prediction for monitoring of pharmaceuticals using spectroscopy
|
EP4180035A1
(en)
|
2021-11-15 |
2023-05-17 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Novel beta-lactone inhibitors of hydrolytic enzymes and their medical and non medical uses
|
WO2023110918A1
(en)
|
2021-12-14 |
2023-06-22 |
Cdr-Life Ag |
Dual mhc-targeting t cell engager
|
WO2023154824A1
(en)
|
2022-02-10 |
2023-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that broadly target coronaviruses
|
WO2023164474A1
(en)
|
2022-02-23 |
2023-08-31 |
Amgen Inc. |
Cancer treatment targeting dll3
|
WO2023192881A1
(en)
|
2022-03-28 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
US20230357446A1
(en)
|
2022-04-11 |
2023-11-09 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for universal tumor cell killing
|
WO2023203172A1
(en)
|
2022-04-20 |
2023-10-26 |
Proxygen Gmbh |
Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
|
WO2023218027A1
(en)
|
2022-05-12 |
2023-11-16 |
Amgen Research (Munich) Gmbh |
Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
|
WO2023237366A1
(en)
|
2022-05-27 |
2023-12-14 |
Sanofi |
Anti-bcma antibodies
|
US20240109965A1
(en)
|
2022-06-14 |
2024-04-04 |
Ablynx N.V. |
Immunoglobulin single variable domains targeting t cell receptor
|
WO2024030829A1
(en)
|
2022-08-01 |
2024-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
|
WO2024054822A1
(en)
|
2022-09-07 |
2024-03-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Engineered sars-cov-2 antibodies with increased neutralization breadth
|
WO2024056758A1
(en)
|
2022-09-14 |
2024-03-21 |
Cdr-Life Ag |
Mage-a4 peptide dual t cell engagers
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
WO2024064826A1
(en)
|
2022-09-22 |
2024-03-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
WO2024068944A1
(en)
|
2022-09-30 |
2024-04-04 |
Sanofi |
Anti-cd28 antibodies
|
WO2024077044A1
(en)
|
2022-10-05 |
2024-04-11 |
Amgen Inc. |
Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
|
WO2024092033A1
(en)
|
2022-10-26 |
2024-05-02 |
Amgen Inc. |
Multispecific molecules for clearance of immunoglobulins in the treatment of autoantibody-induced diseases
|